Menu
Big data is changing every possible industry. It’s helping us make better financial decisions, divide scarce farming resources, and plan our cities, streets, and buildings.
But in pharma, it still takes a decade to bring a new drug to market, with a staggering 90% failure rate for drugs in development.
A major issue lies in the lack of integration and standardization of research data, with thousands of research groups working independently and generating disparate data.
What if we had a platform capable of integrating all types of data, related to all types of diseases? CytoReason’s Disease Model Platform is the first AI model designed to do just that. It maps treatments, patient groups, and disease mechanisms, while constantly evolving and learning.
The Disease Model Platform offers layers of pre-computed data, similar to how navigation apps provide data about streets, buildings, and addresses.
These layers can include transcriptomic data from clinical trials, proteomic data, and single-cell data. By offering multiple models for various diseases, the platform enables users to identify potential targets, prioritize treatments, stratify patients, and recognize possible drug combinations.
The platform allows you to integrate user-generated data, and test hypotheses across treatments. It can even help you understand the cause of the disease and identify potential prevention methods.
Perhaps the most significant advantage of the Disease Model Platform is its ability to compare assets across different diseases. With a single standard for disease models, users can answer critical questions such as:
“Which other patients might benefit most from my drug?”
“What other diseases are relevant for the drug I developed?”
Or “How does my drug compare to other “Standard of Care” drugs in a specific disease?”
And with that, you can identify new opportunities, increase success rates, and shorten drug development cycles.
Find out more about the Disease Model Platform by watching our new video and please be in touch if you’d like to hear more.
| | | All rights reserved CytoReason LTD © 2022 |